191 related articles for article (PubMed ID: 30928228)
1. Impact of bone marrow plasma cells percentage on survival at diagnosis and pre-transplant period in newly diagnosed multiple myeloma: Experience of a single center from Turkey.
Ciftciler R; Goker H; Buyukasık Y; Aladag E; Saglam EA; Demiroglu H
Transfus Apher Sci; 2019 Jun; 58(3):313-317. PubMed ID: 30928228
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow plasma cell assessment before peripheral blood stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplantation.
Lee SE; Yoon JH; Shin SH; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Lee JW; Min WS; Park CW; Kim M; Min CK
Biomed Res Int; 2014; 2014():982504. PubMed ID: 24895639
[TBL] [Abstract][Full Text] [Related]
3. Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma.
Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Leuk Lymphoma; 2017 Feb; 58(2):308-315. PubMed ID: 27390076
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma in serologic complete remission after autologous stem cell transplantation: impact of bone marrow plasma cell assessment by conventional morphology on disease progression.
Fernández de Larrea C; Tovar N; Rozman M; Rosiñol L; Aróstegui JI; Cibeira MT; Rovira M; Yagüe J; Bladé J
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1084-7. PubMed ID: 21215814
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation.
Hwang IH; Chung JS; Shin HJ; Choi YJ; Song MK; Seol YM; Cho GJ; Choi BG; Choi MK; Choi BK; Ahn KH; Shin KH; Lee HS; Nam HS; Hwang JM
Korean J Intern Med; 2011 Mar; 26(1):76-81. PubMed ID: 21437166
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
7. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation.
Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Therneau TM; Kyle RA; Greipp PR; Gertz MA
Am J Hematol; 2001 Dec; 68(4):269-75. PubMed ID: 11754416
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant.
Sucak GT; Aki SZ; Yüzbaşioğlu B; Akyürek N; Yağci M; Bağriaçik U; Haznedar R
Leuk Lymphoma; 2011 Jul; 52(7):1281-9. PubMed ID: 21599578
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.
Liu H; Yuan C; Heinerich J; Braylan R; Chang M; Wingard J; Moreb J
Leuk Lymphoma; 2008 Feb; 49(2):306-14. PubMed ID: 18231918
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
[TBL] [Abstract][Full Text] [Related]
11. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.
Paiva B; Vidriales MB; Mateo G; Pérez JJ; Montalbán MA; Sureda A; Montejano L; Gutiérrez NC; García de Coca A; de las Heras N; Mateos MV; López-Berges MC; García-Boyero R; Galende J; Hernández J; Palomera L; Carrera D; Martínez R; de la Rubia J; Martín A; González Y; Bladé J; Lahuerta JJ; Orfao A; San-Miguel JF;
Blood; 2009 Nov; 114(20):4369-72. PubMed ID: 19755674
[TBL] [Abstract][Full Text] [Related]
12. Impact of Pre-transplant and Post-transplant Remission Status of Patients on Survival in Newly Diagnosed Multiple Myeloma.
Ciftciler R; Goker H; Buyukasık Y; Aladag E; Demiroglu H
Indian J Hematol Blood Transfus; 2019 Oct; 35(4):655-661. PubMed ID: 31741617
[TBL] [Abstract][Full Text] [Related]
13. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation for multiple myeloma: Long-term results.
Kumar L; Boya RR; Pai R; Harish P; Mookerjee A; Sainath B; Patekar MB; Sahoo RK; Malik PS; Sharma OD; Gupta R
Natl Med J India; 2016; 29(4):192-199. PubMed ID: 28050994
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis.
Muchtar E; Gertz MA; Kourelis TV; Sidana S; Go RS; Lacy MQ; Buadi FK; Dingli D; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Lisa Hwa Y; Gonsalves W; Warsame R; Russell S; Lust JA; Lin Y; Zeldenrust S; Rajkumar SV; Kyle RA; Kumar SK; Dispenzieri A
Leukemia; 2020 Apr; 34(4):1135-1143. PubMed ID: 31758090
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation.
Al Saleh AS; Sidiqi MH; Muchtar E; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1402-1405. PubMed ID: 32422250
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
[TBL] [Abstract][Full Text] [Related]
18. [Effects of Pre-Transplant CONUT and Post-Transplant MRD on Prognosis of Patients with Multiple Myeloma after Auto-HSCT].
Xiong YY; Zhou Q; Chen L; Yu W; Zhang HB; Chen JB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):146-154. PubMed ID: 38387913
[TBL] [Abstract][Full Text] [Related]
19. Effect of complete response on outcome following autologous stem cell transplantation for myeloma.
Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Larson D; Therneau TM; Kyle RA; Litzow MR; Greipp PR; Gertz MA
Bone Marrow Transplant; 2000 Nov; 26(9):979-83. PubMed ID: 11100277
[TBL] [Abstract][Full Text] [Related]
20. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
